Click here to text our team
Skip to main content

TearCare's Olympia Study demonstrates improvement in patients with Dry Eye Disease

The recently published Olympia Study showed that a single treatment of TearCare safely and successfully treats the signs and symptoms of Dry Eye Disease (DED) in patients with Meibomian Gland Dysfunction (MGD).

The study also demonstrated comparable findings to the thermal pulsation device, Lipiflow.

Interestingly, a greater proportion of patients in the TearCare group showed better symptomatic relief compared to the LipiFlow group when reviewing the OSDI dry eye questionnaire.

Click the link below for more details on the study details:

TearCare Study



Dr Kambiz Silani Chief Clinical Director

You Might Also Enjoy...